FDA approval for GSK, Roche drugs could boost balance sheets

09/17/2008 | Reuters

The FDA is set to hand down by Friday its decisions on GlaxoSmithKline's Promacta and Roche Holding's Actemra, a move that may boost the drugmakers' market shares. Citigroup analysts estimated that by 2012, Promacta -- a drug to treat a rare blood disorder -- could generate $509.6 million, while Actemra -- a rheumatoid arthritis medicine -- could bring in $638 million.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA